跳轉至內容
Merck
全部照片(1)

Key Documents

View All Documentation

M-123

Supelco

美托洛尔 酒石酸酯 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C15H25NO3 · 0.5 C4H6O6
CAS號碼:
56392-17-7
分子量：:
342.41
EC號碼:
200-659-6
MDL號碼:
MFCD23141017
分類程式碼代碼:
41116107
PubChem物質ID:
329817863
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in methanol (as free base)

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

2-8°C

SMILES 字串

CC(C)NCC(COC1=CC=C(CCOC)C=C1)O.CC(C)NCC(COC2=CC=C(CCOC)C=C2)O.OC(C(O)=O)C(C(O)=O)O

InChI

1S/2C15H25NO3.C4H6O6/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-1(3(7)8)2(6)4(9)10/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)

InChI 密鑰

YGULWPYYGQCFMP-UHFFFAOYSA-N

基因資訊

human ... ADRB1(153)

相關類別

一般說明

经认证的溶液标准品，适用于通过LC-MS/MS或GC/MS进行临床毒理学或法医分析。美托洛尔用于多种心脏病的治疗，包括高血压，心绞痛和心动过速。这种β受体阻滞剂以Lepressor和Toprol XL®的商品名出售。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Toprol XL is a registered trademark of Astrazeneca AB

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 2

1 of 2

美托洛尔 (+)-酒石酸盐 Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1076

美托洛尔 (+)-酒石酸盐

阿替洛尔 ≥98% (TLC), powder

Sigma-Aldrich

A7655

阿替洛尔

A L Vertkin et al.
Klinicheskaia meditsina, 91(3), 31-35 (2013-06-26)
Patients with acute coronary syndrome and elevated ST segment in the pre-hospital phase were treated with metoprolol succinate (MS) and thrombolytic therapy. Severe and moderate pain decreased by 54.1 and 16.1% respectively within 60 min after MS intake. Systolic (SAP)
Iu M Alekseeva et al.
Kardiologiia, 52(11), 86-91 (2012-12-15)
We present analysis of a case history of a patient with rare congenital heart disorder - Bland-White-Garland syndrome. The 25 years old women was first diagnosed with this disorder during an examination in the cardiological department of the Moscow clinical
Thomas Kahan et al.
European journal of clinical investigation, 43(2), 141-151 (2013-01-03)
Although stable angina pectoris often carries a favourable prognosis, it remains important to identify patients with an increased risk of cardiovascular (CV) complications. Many new markers of disease activity and prognosis have been described. We evaluated whether common and easily
Michel De Pauw et al.
Acta cardiologica, 68(2), 205-207 (2013-05-28)
The concept of chronotropic incompetence may have to be fine-tuned in an era of proven benefit of heart rate reducing therapy. It is illustrated in three patients with heart failure referred for heart transplantation evaluation. In patients one and two
V A Iakushev et al.
Sudebno-meditsinskaia ekspertiza, 55(5), 46-48 (2013-01-01)
This paper reports the results of analysis of the metoprolol succinate tablets fabricated by two different manufacturers, Akrikhin (Russia) and AstraZeneka (Sweden) by near-IR spectroscopy in the combination with the chemometric processing of the data obtained (discriminative analysis). It is
查看所有相關論文

文章

Bioanalytical Microsampling using Biocompatible SPME and Benefits over Dried Blood Spots

This study compares the use of SPME LC Tips to dried blood spots (DBS) in terms of extraction efficiency and detection limits of target analytes from whole blood.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務